In a promising development in the fight against Ebola, health authorities in the Democratic Republic of the Congo (DRC) have launched a groundbreaking treatment trial just six weeks after the outbreak was declared a public health emergency. This initiative, aimed at testing two potential therapies, comes as the country grapples with the severe impacts of the Bundibugyo strain of the virus, which has already claimed hundreds of lives.
A Race Against Time
On 17 May, the World Health Organization (WHO) declared the Ebola outbreak in the Ituri province a public health emergency, prompting unprecedented urgency in research and treatment efforts. By 9 July, the outbreak had resulted in 1,792 confirmed cases and 625 deaths, indicating a dire need for effective medical intervention.
Mireille Kahindo, a 35-year-old nurse and Ebola survivor, recently emerged from a treatment centre to hold her 16-month-old son, Micky Paul, offering a glimmer of hope amidst the crisis. However, for many in Bunia, the capital of Ituri, the situation remains grim. Local residents, like banana seller Neema Haba, express growing frustration. “Financially, we are being driven to the brink by this outbreak,” she lamented. “We are struggling to provide for our children.”
Overcoming Challenges in Response Efforts
The response to the outbreak has relied heavily on fundamental public health strategies, including case identification, isolation, and contact tracing. While approximately 75% of known contacts are being tracked, efforts are hindered by a lack of trust in authorities and a highly mobile population. Moreover, protests from frontline health workers over unpaid salaries have further complicated the situation, leaving communities vulnerable.
Ovide Maliabo, a driver for a burial team, described the dangers of their work amidst local scepticism. “At one point, we narrowly escaped being lynched,” he recounted, highlighting the risks that health workers face daily. Bahati John, the team leader, echoed these sentiments, revealing that they had not been compensated since beginning their work in mid-May. “We are the breadwinners of our families, and our families are suffering,” he stated, illustrating the challenges faced by those on the frontlines.
New Hope with Experimental Treatments
In a bid to combat this escalating crisis, the Partners treatment trial has commenced, featuring two potential therapies: remdesivir, developed by Gilead Sciences, and MBP134, a monoclonal antibody from Mapp Biopharmaceutical. Patients enrolled in the trial will receive either of the drugs, a combination of both, or standard supportive care.
Both treatments have previously demonstrated efficacy against the Bundibugyo virus in animal studies, and now researchers are eager to determine their effectiveness in human cases. “We want to see if they indeed can lower mortality,” stated Professor Laurens Liesenborghs from the Institute of Tropical Medicine in Antwerp, affirming the trial’s significance.
The trial’s structure is designed to be adaptable, allowing additional treatments to be incorporated as they become available. Between 700 to 1,000 patients are expected to be recruited, with initial supplies sufficient for 1,200 participants, thanks to donations from Gilead and the US government.
The Importance of Inclusivity in Trials
One notable aspect of the Partners trial is its inclusivity; patients of all ages, including pregnant and breastfeeding women, are eligible to participate. This approach acknowledges the high stakes involved, as many of these individuals face significant risks from the disease. “The benefit is potentially very high because you offer a potentially life-saving treatment to someone who has a very high chance of dying,” Liesenborghs explained.
Professor Amanda Rojek, principal investigator from the University of Oxford, praised the swift initiation of the trial, comparing it favourably to previous outbreaks in West Africa. “We’ve managed to achieve that in kind of six weeks since the outbreak was first announced,” she said, underscoring the effectiveness of the scientific leadership in the DRC.
Why it Matters
The launch of this treatment trial represents a crucial turning point in the ongoing battle against Ebola in the DRC. As researchers push forward with the hope of discovering effective therapies, the success of these trials could not only save countless lives but also restore trust within the affected communities. In an environment marked by fear and uncertainty, the promise of new treatments offers a beacon of hope, potentially paving the way for improved public health responses in future outbreaks.
